Back to Search Start Over

Quality of life measurement in teledermatology. Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Teledermatology.

Authors :
Chernyshov, P. V.
Finlay, A. Y.
Tomas‐Aragones, L.
Tognetti, L.
Moscarella, E.
Pasquali, P.
Manolache, L.
Pustisek, N.
Svensson, A.
Marron, S. E.
Bewley, A.
Salavastru, C.
Suru, A.
Koumaki, D.
Linder, D.
Abeni, D.
Augustin, M.
Blome, C.
Salek, S. S.
Evers, A. W. M.
Source :
Journal of the European Academy of Dermatology & Venereology. Feb2024, Vol. 38 Issue 2, p254-264. 11p.
Publication Year :
2024

Abstract

Many events, including the COVID‐19 pandemic, have accelerated the implementation of teledermatology pathways within dermatology departments and across healthcare organizations. Quality of Life (QoL) assessment in dermatology is also a rapidly developing field with a gradual shift from theory to practice. The purpose of this paper organized jointly by the European Academy of Dermatology and Venereology (EADV) Task Force (TF) on QoL and patient‐oriented outcomes and the EADV TF on teledermatology is to present current knowledge about QoL assessment during the use of teledermatology approaches, including data on health‐related (HR) QoL instruments used in teledermatology, comparison of influence of different treatment methods on HRQoL after face‐to‐face and teledermatology consultations and to make practical recommendations concerning the assessment of QoL in teledermatology. The EADV TFs made the following position statements: HRQoL assessment may be an important part in most of teledermatology activities; HRQoL assessment may be easily and effectively performed during teledermatology consultations. It is especially important to monitor HRQoL of patients with chronic skin diseases during lockdowns or in areas where it is difficult to reach a hospital for face‐to‐face consultation; regular assessment of HRQoL of patients with skin diseases during teledermatology consultations may help to monitor therapy efficacy and visualize individual patient's needs; we recommend the use of the DLQI in teledermatology, including the use of the DLQI app which is available in seven languages; it is important to develop apps for dermatology‐specific HRQoL instruments for use in children (for example the CDLQI and InToDermQoL) and for disease‐specific instruments. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
09269959
Volume :
38
Issue :
2
Database :
Academic Search Index
Journal :
Journal of the European Academy of Dermatology & Venereology
Publication Type :
Academic Journal
Accession number :
175055032
Full Text :
https://doi.org/10.1111/jdv.19570